celecoxib has been researched along with etodolac in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Anderluh, M; Brunskole, M; Gobec, S; Lanisnik Rizner, T; Stefane, B; Stojan, J; Zorko, K | 1 |
| Anzellotti, P; Anzini, M; Biava, M; Botta, M; Cirilli, R; Ferretti, R; Forli, S; Gallinella, B; Ghelardini, C; Giordani, A; La Torre, F; Makovec, F; Manetti, F; Norcini, M; Patrignani, P; Pergola, C; Poce, G; Porretta, GC; Rossi, A; Sautebin, L; Supino, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Wallace, JL | 1 |
| Hawkey, CJ; Jackson, LM | 1 |
| Browning, RA; Burgess, FW | 1 |
| Lane, S; Linley, W; Maskrey, N; McQuade, C; Micklewright, R; Thompson, F | 1 |
| Meena, S; Nageswara Rao, R; Raghuram Rao, A | 1 |
| Fraunfelder, FW; Mehelas, TJ; Solomon, J | 1 |
| Calvo, N; Iversen, E; Munck, LK | 1 |
| Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J | 1 |
| Behari, J; Leoni, L; Micsenyi, A; Monga, SP; Muller, P; Otruba, W; Sekhon, SS; Thompson, MD; Zeng, G | 1 |
| Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA | 1 |
| Inoue, N; Ito, S; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y | 1 |
| Armeanu-Ebinger, S; Ellerkamp, V; Fuchs, J; Lieber, J; Nagel, C; Warmann, SW; Wenz, J | 1 |
| Asano, R; Saito, T; Tamura, D | 1 |
| Kanbayashi, Y; Konishi, H | 1 |
| Pedersen, L; Schmidt, M; Sørensen, HT | 1 |
| Bamps, D; de Hoon, J; Marynissen, H; Mergaerts, D | 1 |
| Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E | 1 |
5 review(s) available for celecoxib and etodolac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Gene Expression; Humans; Ibuprofen; Indomethacin; Isoenzymes; Meloxicam; Membrane Proteins; Naproxen; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thiazines; Thiazoles | 1999 |
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etodolac; Humans; Lactones; Meloxicam; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2000 |
Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Meloxicam; Membrane Proteins; Practice Guidelines as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2003 |
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays | 2005 |
1 trial(s) available for celecoxib and etodolac
| Article | Year |
|---|---|
Does etodolac affect TRPA1 functionality
Topics: Adolescent; Adult; Celecoxib; Etodolac; Humans; Male; Middle Aged; Suppuration; TRPA1 Cation Channel; Young Adult | 2023 |
16 other study(ies) available for celecoxib and etodolac
| Article | Year |
|---|---|
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
Topics: Amino Acid Sequence; Ascomycota; Benzopyrans; Enzyme Inhibitors; Fungal Proteins; Melanins; Models, Molecular; Molecular Sequence Data; Oxidoreductases Acting on CH-CH Group Donors; Recombinant Proteins; Structural Homology, Protein; Substrate Specificity | 2008 |
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
Topics: Acetic Acid; Alcohols; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Carrageenan; Cells, Cultured; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Edema; Enzyme Activation; Enzyme Inhibitors; Ethers; Humans; Isoenzymes; Male; Mice; Models, Chemical; Molecular Structure; Pain; Pain Measurement; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Conjunctivitis; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Isoxazoles; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders | 2006 |
[Intestinal side effects of COX-2 inhibitors].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Etodolac; Female; Humans; Ileostomy; Intestinal Obstruction; Intestinal Perforation; Lactones; Middle Aged; Pyrazoles; Sigmoid Diseases; Sulfonamides; Sulfones; Ulcer | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans | 2006 |
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Etodolac; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Humans; Liver Neoplasms; Pyrazoles; Sulfonamides; Trans-Activators; Tumor Cells, Cultured | 2007 |
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Utilization Review; Drugs, Generic; Etodolac; Humans; Incidence; Lactones; Male; Medical Records; Middle Aged; Myocardial Infarction; Naproxen; Prevalence; Prognosis; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Texas; Veterans | 2008 |
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Edema; Etodolac; gamma-Aminobutyric Acid; Indicators and Reagents; Ligation; Male; Mice; Pain; Pain Measurement; Pregabalin; Pyrazoles; Sciatic Neuropathy; Sulfonamides | 2009 |
Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Topics: Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Etodolac; Hepatoblastoma; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrazoles; Pyrimidinones; Sulfonamides; Tissue Distribution; Tumor Cells, Cultured | 2013 |
Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dogs; Etodolac; Female; Immunohistochemistry; Mammary Neoplasms, Experimental; Pyrazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2014 |
Predictive Factors for NSAIDs-related Gastrointestinal Toxicity: Can COX-2 Selective Inhibtor Prevent it?.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents; Aspirin; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Digestive System; Etodolac; Female; Humans; Logistic Models; Male; Middle Aged; Phenylpropionates; Protective Factors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Stomach Diseases; Stomach Ulcer | 2015 |
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors | 2022 |
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
Topics: Bariatric Surgery; Bariatrics; Celecoxib; Cyclooxygenase 2 Inhibitors; Etodolac; Etoricoxib; Humans; Solubility | 2023 |